KRBP Kiromic BioPharma Inc.

FDA Catalyst Company
0.35
+0.01  (+4%)
Previous Close 0.33
Open 0.33
52 Week Low 0.2993
52 Week High 11
Market Cap $5,462,690
Shares 15,751,701
Float 15,241,985
Enterprise Value $-18,519,962
Volume 196,151
Av. Daily Volume 212,866
COMPANY CASH DATABASE
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
BIOTECH EARNINGS CALENDAR
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

    Recent Corporate Highlights Include:

    • New Leadership Appointed at the Company, Board of Director Level
    • Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform
    • Progressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) Production
    • Enhanced Kiromic's Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking Technology
    • Expansion and Redesign of In-house cGMP Manufacturing Facility
    • DIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy Development
    • Cash Position $15,123,100 as of March 31, 2022

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company")…

    View Full Article
  2. Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

    Company Provides Regulatory Update on Progress to Address Previously Outlined Chemistry, Manufacturing, and Control (CMC) Issues Related to Clinical Hold on Investigational New Drug Applications (INDs)

    A Type A FDA Meeting Will Not Be Pursued

    Company Announces Ongoing Progress Towards the Implementation by the Beginning of the Third Quarter of 2022 of a Current Good Manufacturing Practice (cGMP) Mammalian Master Cell Bank (mMCB), a Key Component to Manufacture a GMP-Grade Retroviral Vector for Gamma Delta T (GDT) Cell Engineering

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform…

    View Full Article
  3. Kiromic BioPharma Announces Availability of Company's Current Corporate Presentation

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Company's most recent corporate presentation. The updated presentation can be accessed on the investor relations section of the Company's website. The corporate presentation was also filed as a Form 8-K with the Securities and Exchange Commission. See the updated corporate presentation here Kiromic BioPharma April 2022 Corporate Presentation.

    About Kiromic BioPharma

    Kiromic BioPharma, Inc…

    View Full Article
  4. Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

    Highlights Include Company's Progress in the Following Areas:

    • Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform
    • Key Hires in Research & Development, Clinical Translational Medicine and Clinical Trial Preparation
    • Completion of Approximately 90% of In-house cGMP Facility Expansion and Redesign
    • Launch of DIAMOND® Artificial Intelligence (AI) 2.0 Platform for Identification and Selection of Immunotherapy Targets, which Now Includes Nearly Two Billion Data Points

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform…

    View Full Article
  5. Kiromic Biopharma Announces Filing of Form 12b-25

    Company Expects to File 2021 Form 10-K Prior to 15-day Extension Period Expiration

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces that it has filed a Form 12b-25 with the SEC to obtain a 15-calendar day extension to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 Form 10-K"). The Company expects to file its 2021 Form 10-K during the 15-calendar day extension period.

    About Kiromic BioPharma

    Kiromic BioPharma…

    View Full Article
View All Kiromic BioPharma Inc. News
Market Data copyright © 2017 QuoteMedia. Data delayed 15–35 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.